REG - Venture Life Group - Directorate Change

Venture LifeAnnouncement

20/12/2021 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211220:nRST2514Wa&default-theme=true

RNS Number : 2514W  Venture Life Group PLC  20 December 2021

20 December 2021

Venture Life Group plc

("Venture Life" or the "Company")

Directorate Change

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, is pleased to announce that
Mr Daniel Wells, appointed as Chief Financial Officer at the time of the
trading update announcement on 1 December 2021, has joined the Board with
immediate effect.

Further information on Daniel Wells

Daniel James Wells (aged 34) has in the last five years been a director of The
Green (Stoke Park) Management Company Limited and is currently a director of
Susandan Limited.

There is no further information on Daniel Wells required to be disclosed under
Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

For further information please contact:

 Venture Life Group PLC                                 +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Broker)               +44 (0) 20 7397 8900
 Stephen Keys / Camilla Hume
 Russell Kerr / Michael Johnson (Sales)

 N+1 Singer (Joint Broker)                              +44 (0) 20 7496 3000
  Shaun Dobson / Alaina Wong (Corporate Finance)
  Jonathan Dighe (Sales)

 

 

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in both the UK and Italy, the Group's
product portfolio includes some key products such as the UltraDEX and Dentyl
oral care product ranges, food supplements for lowering cholesterol and
maintaining brain function, medical devices for women's intimate healthcare
and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK these are supplied direct by the company, outside of the
UK they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the
Group also provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLBDDIGDDGBG